Click Here for 5% Off Your First Aladdin Purchase!

tumour necrosis factor shed form, CAS No.rp175336, tumor necrosis factor receptor 1

  • Moligand™
Features and benefits
    Item Number
    rp175336
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp175336-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp175336-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product Nametumour necrosis factor shed form, CAS No.rp175336
    Synonymscachectin;necrosin;TNF alpha soluble form;TNF shed form;tumor necrosis factor soluble form
    GradeMoligand™
    Mechanism of actiontumor necrosis factor receptor 1

    Associated Targets

    TNFRSF1A Tchem Tumor necrosis factor receptor superfamily member 1A 0 Activities

    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp175336

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate Namescachectin;necrosin;TNF alpha soluble form;TNF shed form;tumor necrosis factor soluble form
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP.  (2008)  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review..  Pharmacol Ther,  117  (2): (244-79).  [PMID:18155297]
    2. Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, Harcourt K, Reckless J, MacDonald TT, Ray KP et al..  (2018)  Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease..  Sci Rep,  (1): (4941).  [PMID:29563546]
    3. Gahring LC, Carlson NG, Kulmar RA, Rogers SW.  (1996)  Neuronal expression of tumor necrosis factor alpha in the murine brain..  Neuroimmunomodulation,  (5): (289-303).  [PMID:9218250]

    Solution Calculators